SCHEMBL4129415

SCHEMBL4129415

COc1ccc(C2CCCCCC2=O)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 13/20 0.50
PDE4B Q07343 12/20 0.50
PDE4C Q08493 11/20 0.50
PDE4D Q08499 11/20 0.50
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NR3C1 P04150 1/20 0.44
GFER P55789 1/20 0.43
CYP3A4 P08684 2/20 0.43
VEGFA P15692 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX15 P16050 1/20 0.43
CREBBP Q92793 1/20 0.43
KDM4E B2RXH2 1/20 0.43
PDE5A O76074 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11844345 0.98 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DGAA
SCHEMBL7419187 0.89 PDE4B (0.66) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL28890937 0.87 PDE4B (0.43) PDE4APDE4BPDE4CPDE4DCYP3A4
SCHEMBL17185831 0.85 MAPK1 (0.45) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL17185968 0.85 ALDH1A1 (0.44) PDE4APDE4BPDE4CPDE4DGAA
SCHEMBL18418762 0.85 ALDH1A1 (0.52) PDE4APDE4BPDE4CPDE4DGAA
SCHEMBL31615321 0.82 APP (0.52) PDE4APDE4BPDE4CPDE4DRAB9A
SCHEMBL18422425 0.82 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DRAB9A
SCHEMBL28414869 0.81 PTAFR (0.51) ALDH1A1LMNAMAPTKMT2A
SCHEMBL7209583 0.81 ALDH1A1 (0.54) PDE4AALDH1A1LMNACYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP PDE4A 1821/4885PDE4B 1676/4885PDE4C 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.